MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

BeiGene Ltd ADR

Closed

SectorHealthcare

274.91 1.78

Overview

Share price change

24h

Current

Min

268.22

Max

275.62

Key metrics

By Trading Economics

Income

-31M

-152M

Sales

126M

1.1B

Profit margin

-13.467

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+18.41% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

22B

Previous open

273.13

Previous close

274.91

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

BeiGene Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 sty 2025, 15:59 UTC

Major Market Movers

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

27 lis 2024, 15:22 UTC

Major Market Movers

BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment

21 lis 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

22 paź 2024, 18:39 UTC

Major Market Movers

Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment

23 kwi 2024, 14:58 UTC

Major Market Movers

BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment

27 lut 2025, 11:07 UTC

Earnings

BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC

27 lut 2025, 11:06 UTC

Earnings

BeiGene 4Q Global BRUKINSA Rev of $828M >ONC

27 lut 2025, 11:06 UTC

Earnings

BeiGene 4Q Loss/Shr 11c >ONC

27 lut 2025, 11:06 UTC

Earnings

BeiGene 4Q Rev $1.13B >ONC

12 lis 2024, 11:01 UTC

Earnings

BeiGene 3Q Loss/Shr 9c >BGNE

12 lis 2024, 11:01 UTC

Earnings

BeiGene 3Q Rev $1B >BGNE

7 sie 2024, 10:05 UTC

Earnings

BeiGene 2Q Loss/Shr $1.15 >BGNE

7 sie 2024, 10:04 UTC

Earnings

BeiGene 2Q Rev $929M >BGNE

8 maj 2024, 10:02 UTC

Earnings

BeiGene 1Q Loss/Shr 19c >BGNE

8 maj 2024, 10:01 UTC

Earnings

BeiGene 1Q Loss $251.2M >BGNE

8 maj 2024, 10:01 UTC

Earnings

BeiGene 1Q Rev $752M >BGNE

Peer Comparison

Price change

BeiGene Ltd ADR Forecast

Price Target

By TipRanks

18.41% upside

12 Months Forecast

Average 320.95 USD  18.41%

High 359.47 USD

Low 259 USD

Based on 12 Wall Street analysts offering 12 month price targets forBeiGene Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Operating profit

$

About BeiGene Ltd ADR

BeiGene Ltd